NI202100025A - Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contienen la misma. - Google Patents
Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contienen la misma.Info
- Publication number
- NI202100025A NI202100025A NI202100025A NI202100025A NI202100025A NI 202100025 A NI202100025 A NI 202100025A NI 202100025 A NI202100025 A NI 202100025A NI 202100025 A NI202100025 A NI 202100025A NI 202100025 A NI202100025 A NI 202100025A
- Authority
- NI
- Nicaragua
- Prior art keywords
- same
- preparing
- pharmaceutical compositions
- compositions containing
- bcl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Nueva sal y formas cristalinas relacionadas del Compuesto A: en donde la sal es la sal hidrógeno sulfato, caracterizada por su diagrama de difracción de rayos X de polvo, método para preparar la misma y composiciones farmacéuticas que la contienen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18306430 | 2018-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI202100025A true NI202100025A (es) | 2021-08-24 |
Family
ID=64270773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI202100025A NI202100025A (es) | 2018-10-31 | 2021-04-09 | Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contienen la misma. |
Country Status (37)
Country | Link |
---|---|
US (1) | US20210355108A1 (es) |
EP (1) | EP3873894B1 (es) |
JP (1) | JP2022506137A (es) |
KR (1) | KR20210092750A (es) |
CN (1) | CN112969693A (es) |
AR (1) | AR116921A1 (es) |
AU (1) | AU2019370926A1 (es) |
BR (1) | BR112021007194A2 (es) |
CA (1) | CA3117559C (es) |
CL (1) | CL2021000947A1 (es) |
CO (1) | CO2021005077A2 (es) |
CR (1) | CR20210211A (es) |
CY (1) | CY1126057T1 (es) |
DK (1) | DK3873894T3 (es) |
DO (1) | DOP2021000074A (es) |
EA (1) | EA202191143A1 (es) |
ES (1) | ES2943511T3 (es) |
FI (1) | FI3873894T3 (es) |
GE (1) | GEP20237494B (es) |
HR (1) | HRP20230563T1 (es) |
HU (1) | HUE062000T2 (es) |
IL (1) | IL282565A (es) |
JO (1) | JOP20210072A1 (es) |
LT (1) | LT3873894T (es) |
MA (1) | MA54063B1 (es) |
MX (1) | MX2021004934A (es) |
NI (1) | NI202100025A (es) |
PE (1) | PE20211503A1 (es) |
PH (1) | PH12021550790A1 (es) |
PL (1) | PL3873894T3 (es) |
PT (1) | PT3873894T (es) |
RS (1) | RS64236B1 (es) |
SG (1) | SG11202103594XA (es) |
SI (1) | SI3873894T1 (es) |
TW (1) | TWI791916B (es) |
WO (1) | WO2020089281A1 (es) |
ZA (1) | ZA202102783B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL300145A (en) | 2020-07-31 | 2023-03-01 | Servier Lab | A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations |
WO2022090443A1 (en) | 2020-10-30 | 2022-05-05 | Les Laboratoires Servier | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor |
AR125205A1 (es) | 2021-03-24 | 2023-06-21 | Servier Lab | Nuevo proceso para la síntesis de derivados del ácido 5-{5-cloro-2-[(3s)-3-[(morfolin-4-il)metil]-3,4-dihidroisoquinolina-2(1h)-carbonil]fenil}-1,2-dimetil-1h-pirrol-3-carboxílico y su aplicación para la producción de compuestos farmacéuticos |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004057195A1 (de) * | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
WO2006073292A1 (en) * | 2005-01-06 | 2006-07-13 | Cj Corporation | Inorganic acid salts of sibutramine |
TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
CN101962387B (zh) * | 2010-09-13 | 2013-01-30 | 成都雅途生物技术有限公司 | 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法 |
CN103664753B (zh) * | 2012-09-04 | 2017-04-26 | 上海迪赛诺化学制药有限公司 | 制备阿扎那韦硫酸氢盐a型结晶的方法 |
FR3008975A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP3283486B1 (en) * | 2015-04-15 | 2022-07-27 | BeiGene, Ltd. | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
-
2019
- 2019-10-30 CR CR20210211A patent/CR20210211A/es unknown
- 2019-10-30 US US17/286,936 patent/US20210355108A1/en active Pending
- 2019-10-30 AU AU2019370926A patent/AU2019370926A1/en active Pending
- 2019-10-30 KR KR1020217015833A patent/KR20210092750A/ko unknown
- 2019-10-30 PT PT198009474T patent/PT3873894T/pt unknown
- 2019-10-30 MX MX2021004934A patent/MX2021004934A/es unknown
- 2019-10-30 GE GEAP201915620A patent/GEP20237494B/en unknown
- 2019-10-30 BR BR112021007194-6A patent/BR112021007194A2/pt unknown
- 2019-10-30 LT LTEPPCT/EP2019/079621T patent/LT3873894T/lt unknown
- 2019-10-30 AR ARP190103143A patent/AR116921A1/es unknown
- 2019-10-30 PL PL19800947.4T patent/PL3873894T3/pl unknown
- 2019-10-30 WO PCT/EP2019/079621 patent/WO2020089281A1/en active Application Filing
- 2019-10-30 RS RS20230347A patent/RS64236B1/sr unknown
- 2019-10-30 CN CN201980071289.7A patent/CN112969693A/zh active Pending
- 2019-10-30 FI FIEP19800947.4T patent/FI3873894T3/fi active
- 2019-10-30 JO JOP/2021/0072A patent/JOP20210072A1/ar unknown
- 2019-10-30 SG SG11202103594XA patent/SG11202103594XA/en unknown
- 2019-10-30 MA MA54063A patent/MA54063B1/fr unknown
- 2019-10-30 EP EP19800947.4A patent/EP3873894B1/en active Active
- 2019-10-30 ES ES19800947T patent/ES2943511T3/es active Active
- 2019-10-30 JP JP2021523309A patent/JP2022506137A/ja active Pending
- 2019-10-30 DK DK19800947.4T patent/DK3873894T3/da active
- 2019-10-30 HU HUE19800947A patent/HUE062000T2/hu unknown
- 2019-10-30 SI SI201930557T patent/SI3873894T1/sl unknown
- 2019-10-30 TW TW108139360A patent/TWI791916B/zh active
- 2019-10-30 PE PE2021000597A patent/PE20211503A1/es unknown
- 2019-10-30 HR HRP20230563TT patent/HRP20230563T1/hr unknown
- 2019-10-30 CA CA3117559A patent/CA3117559C/en active Active
- 2019-10-30 EA EA202191143A patent/EA202191143A1/ru unknown
-
2021
- 2021-04-09 NI NI202100025A patent/NI202100025A/es unknown
- 2021-04-09 PH PH12021550790A patent/PH12021550790A1/en unknown
- 2021-04-16 CL CL2021000947A patent/CL2021000947A1/es unknown
- 2021-04-21 DO DO2021000074A patent/DOP2021000074A/es unknown
- 2021-04-21 CO CONC2021/0005077A patent/CO2021005077A2/es unknown
- 2021-04-22 IL IL282565A patent/IL282565A/en unknown
- 2021-04-26 ZA ZA2021/02783A patent/ZA202102783B/en unknown
-
2023
- 2023-05-18 CY CY20231100236T patent/CY1126057T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI202100025A (es) | Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contienen la misma. | |
AR111304A1 (es) | Métodos para sintetizar un inhibidor de mcl-1 | |
CU20190086A7 (es) | Compuestos de heteroarilo bicíclicos 6-6 fusionados útiles como inhibidores de lats | |
PE20201444A1 (es) | Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido | |
MX2021002382A (es) | Sales y formas cristalinas de modulador alosterico positivo gabaa. | |
EA200802119A1 (ru) | Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат | |
ECSP088597A (es) | Sal de sulfato de hidrógeno novedosa | |
CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
MX2021000348A (es) | 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo. | |
CL2017001130A1 (es) | Síntesis de copanlisib y su sal diclorhidrato | |
AR103902A1 (es) | Métodos para preparar buprenorfina | |
NI201500122A (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen. | |
PE20170212A1 (es) | Composicion reactiva basada en bicarbonato de sodio y procedimiento para su produccion | |
CL2016003155A1 (es) | Composiciones de cuidado bucal | |
MX2015013020A (es) | Polimorfos de sovaprevir y metodos de fabricacion de los mismos. | |
IL283656A (en) | New crystalline forms of mcl-1 inhibitor, process for their preparation and pharmaceutical preparations containing them | |
AR100095A1 (es) | Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico | |
AR103020A1 (es) | Formas cristalinas de la sal de monosodio del foramsulfurón | |
MX2021004288A (es) | Nuevo proceso para la sintesis de derivados de piperazinil-etoxi-bromofenilo y su aplicacion en la produccion de compuestos que los contienen. | |
AR107441A1 (es) | Forma cristalina de cobicistat | |
PE20221009A1 (es) | Sintesis de un inhibidor de calicreina plasmatica a escala de proceso | |
ECSP22046595A (es) | Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina | |
AR107790A1 (es) | Formas sólidas de una tienopirimidindiona inhibidora de acc y métodos de producción de la misma | |
TH173862B (th) | ผลิตภัณฑ์ต้านทานการติดไฟที่มีแคลเซียมซัลเฟตเป็นสารพื้น | |
AR101641A1 (es) | Formas sólidas del 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida, sus composiciones y métodos de uso |